HRP20120708T1 - Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti - Google Patents
Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti Download PDFInfo
- Publication number
- HRP20120708T1 HRP20120708T1 HRP20120708TT HRP20120708T HRP20120708T1 HR P20120708 T1 HRP20120708 T1 HR P20120708T1 HR P20120708T T HRP20120708T T HR P20120708TT HR P20120708 T HRP20120708 T HR P20120708T HR P20120708 T1 HRP20120708 T1 HR P20120708T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhalation
- treatment
- pharmaceutical preparation
- inflammatory diseases
- combination
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract 5
- 239000003862 glucocorticoid Substances 0.000 title claims abstract 4
- 229940037128 systemic glucocorticoids Drugs 0.000 title claims abstract 3
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title abstract 2
- 239000000812 cholinergic antagonist Substances 0.000 title abstract 2
- 229940124748 beta 2 agonist Drugs 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 2
- 208000006673 asthma Diseases 0.000 claims abstract 2
- 208000023504 respiratory system disease Diseases 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- 229940015042 glycopyrrolate Drugs 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (6)
1. Kombinacija R,R-glikopirolata, formoterola i glukokortikoida, naznačena time, da je odabrana između budesonida i mometazona ili njihovih fiziološki prihvatljivih soli za liječenje upalnih bolesti.
2. Kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da je upalna bolest respiratorna bolest odabrana između astme i COPD-a, reumatizma ili autoimune bolesti odabrane između reumatoidnog artritisa, glomerulonefritisa, multiple skleroze, Crohnove bolesti, ulcerativnog kolitisa, sistemskog lupusa erythematosusa ili psorijaze.
3. Farmaceutski pripravak za liječenje upalnih bolesti, naznačen time, da sadrži R,R-glikopirolat, formoterol i glukokortikoid odabran između budesonida i mometazona ili njihovih fiziološki prihvatljivih soli.
4. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 3, naznačen time, da je riječ o aerosolu za inhaliranje sa ili bez potisnog sredstva, suhom prašku za inhaliranje, suspenziji za inhaliranje ili otopini za inhaliranje.
5. Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da se nalazi u inhalatoru.
6. Farmaceutski pripravak za uporabu u skladu s bilo kojim patentnim zahtjevom 3 - 5, naznačen time, da se djelatne tvari nalaze u fiksnim ili slobodno određenim kombinacijama za istovremenu, uzastopnu ili odvojenu primjenu zajedno s uobičajenim ekscipijensima, adjuvansima i pomoćnim tvarima u farmaceutskom obliku prikladnom za inhalacijsku primjenu.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75205805P | 2005-12-21 | 2005-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120708T1 true HRP20120708T1 (hr) | 2012-10-31 |
Family
ID=37872413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090498T HRP20090498T1 (hr) | 2005-12-21 | 2009-09-21 | Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja |
HRP20120708TT HRP20120708T1 (hr) | 2005-12-21 | 2012-09-06 | Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090498T HRP20090498T1 (hr) | 2005-12-21 | 2009-09-21 | Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja |
Country Status (20)
Country | Link |
---|---|
US (2) | US8048910B2 (hr) |
EP (2) | EP2098248B1 (hr) |
JP (1) | JP5107933B2 (hr) |
CN (1) | CN101321539B (hr) |
AT (1) | ATE439834T1 (hr) |
AU (1) | AU2006329042B2 (hr) |
CA (2) | CA2824075C (hr) |
CY (2) | CY1110519T1 (hr) |
DE (1) | DE602006008665D1 (hr) |
DK (2) | DK1971369T3 (hr) |
ES (2) | ES2389231T3 (hr) |
HK (1) | HK1123497A1 (hr) |
HR (2) | HRP20090498T1 (hr) |
NO (1) | NO20083090L (hr) |
NZ (2) | NZ568349A (hr) |
PL (2) | PL1971369T3 (hr) |
PT (2) | PT1971369E (hr) |
RU (1) | RU2465915C2 (hr) |
SI (2) | SI2098248T1 (hr) |
WO (1) | WO2007071313A2 (hr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100569235C (zh) * | 2004-02-06 | 2009-12-16 | Meda制药有限及两合公司 | 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 |
LT2068889T (lt) | 2006-08-10 | 2020-02-10 | Roy C. Levitt | Anakinra, naudojama bronchiolito obliteranso sindromo gydymui |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
EP2309858A4 (en) * | 2008-07-31 | 2011-09-14 | Dekel Pharmaceuticals Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
CN101474191B (zh) * | 2009-01-21 | 2011-03-23 | 李虎山 | 一种治疗哮喘和慢性阻塞性肺病的药物组合物 |
TWI792140B (zh) | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
AU2010258751A1 (en) * | 2009-06-09 | 2012-02-02 | Sunovion Respiratory Development Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
UA113832C2 (xx) | 2009-12-23 | 2017-03-27 | Комбінаційна терапія для хозл | |
EP2582373A4 (en) | 2010-06-16 | 2013-10-30 | Bruce Chandler May | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COLLECTIONS AND INFLAMMATION |
US20120077786A1 (en) * | 2010-09-27 | 2012-03-29 | Byron David A | Methods and compositions for disease treatment using inhalation |
CN102416179B (zh) | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
EP2627325A1 (en) | 2010-10-12 | 2013-08-21 | Cipla Limited | Pharmaceutical composition |
WO2012107364A1 (en) * | 2011-02-07 | 2012-08-16 | Scipharm Sàrl | Novel composition for the treatment of cystic fibrosis |
CN102247380A (zh) * | 2011-08-19 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种以布地奈德与茚达特罗为活性成分的复方制剂 |
DK2948148T3 (da) | 2013-01-28 | 2020-10-26 | Incozen Therapeutics Pvt Ltd | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
CA2901421A1 (en) | 2013-03-13 | 2014-10-09 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
RU2672871C2 (ru) | 2013-03-13 | 2018-11-20 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцетиризина и монтелукаста при лечении травматических повреждений |
EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
US20140275517A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
EP3193875B1 (en) | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
US10058661B2 (en) | 2014-12-04 | 2018-08-28 | Norton (Waterford) Limited | Inhalation monitoring system and method |
JP6528314B2 (ja) * | 2015-03-20 | 2019-06-12 | 国立大学法人山口大学 | A(H1N1)pdm09インフルエンザウイルス感染による気管支喘息の予防又は改善剤 |
WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
CN111228257A (zh) * | 2020-03-03 | 2020-06-05 | 中国人民解放军南部战区总医院 | 咯利普兰在制备治疗脓毒症心功能障碍的药物中的应用 |
EP4209219A1 (en) * | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE217612T1 (de) * | 1993-07-02 | 2002-06-15 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
EP0932401A1 (en) | 1996-07-01 | 1999-08-04 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
SI0937041T1 (en) * | 1996-11-11 | 2003-10-31 | Christian R. Noe | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament |
US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
AU7455498A (en) * | 1998-05-29 | 1999-12-20 | Citizen Watch Co. Ltd. | Method of subjecting ink jet printer to preuse treatment |
ES2193726T3 (es) | 1998-08-04 | 2003-11-01 | Jago Res Ag | Formulaciones de aerosol medicinales. |
RO122660B1 (ro) * | 1998-11-13 | 2009-11-30 | Skypepharma Ag | Pulbere inhalabilă uscată |
US6745467B1 (en) * | 1999-02-10 | 2004-06-08 | Canon Kabushiki Kaisha | Method of producing a liquid discharge head |
DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
GB9918760D0 (en) * | 1999-08-09 | 1999-10-13 | Darwin Discovery Ltd | Topical treatment |
US20040028958A1 (en) | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
CN100496608C (zh) | 2001-03-30 | 2009-06-10 | 洁垢技术有限公司 | 药用气溶胶制剂 |
US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
EE200300585A (et) | 2001-05-25 | 2004-04-15 | Pfizer Inc. | PDE4 inhibiitori ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks |
DE60216588T2 (de) | 2001-05-25 | 2007-09-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
GB0207906D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
CA2496699C (en) * | 2002-08-29 | 2012-07-17 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
US20040053902A1 (en) * | 2002-09-13 | 2004-03-18 | Smith C. Steven | Novel composition and method for treatment of upper respiratory conditions |
EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
DK1610787T3 (da) * | 2003-03-28 | 2008-06-02 | Nycomed Gmbh | Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme |
WO2004084897A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
JP2007530917A (ja) | 2003-07-11 | 2007-11-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 改善された周波数決定 |
RU2390330C2 (ru) * | 2003-12-31 | 2010-05-27 | Сайдекс, Инк. | Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид |
CN100569235C (zh) * | 2004-02-06 | 2009-12-16 | Meda制药有限及两合公司 | 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 |
EP1718336B1 (en) * | 2004-02-06 | 2008-06-25 | MEDA Pharma GmbH & Co. KG | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
AU2005210086A1 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
US20070185067A1 (en) * | 2004-02-27 | 2007-08-09 | Altana Pharma Ag | Ciclesonide and glycopyrronium combination |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
DE102004056579A1 (de) * | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid |
US20090298802A1 (en) * | 2005-03-30 | 2009-12-03 | Sequeira Joel A | Pharmaceutical Compositions |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
-
2006
- 2006-12-01 SI SI200631387T patent/SI2098248T1/sl unknown
- 2006-12-01 ES ES09006788T patent/ES2389231T3/es active Active
- 2006-12-01 PL PL06829226T patent/PL1971369T3/pl unknown
- 2006-12-01 JP JP2008546173A patent/JP5107933B2/ja not_active Expired - Fee Related
- 2006-12-01 WO PCT/EP2006/011536 patent/WO2007071313A2/en active Application Filing
- 2006-12-01 EP EP09006788A patent/EP2098248B1/en not_active Revoked
- 2006-12-01 NZ NZ568349A patent/NZ568349A/en unknown
- 2006-12-01 EP EP06829226A patent/EP1971369B1/en active Active
- 2006-12-01 SI SI200630435T patent/SI1971369T1/sl unknown
- 2006-12-01 PL PL09006788T patent/PL2098248T3/pl unknown
- 2006-12-01 CA CA 2824075 patent/CA2824075C/en not_active Expired - Fee Related
- 2006-12-01 PT PT06829226T patent/PT1971369E/pt unknown
- 2006-12-01 AU AU2006329042A patent/AU2006329042B2/en not_active Ceased
- 2006-12-01 CA CA2632780A patent/CA2632780C/en not_active Expired - Fee Related
- 2006-12-01 DK DK06829226T patent/DK1971369T3/da active
- 2006-12-01 NZ NZ591969A patent/NZ591969A/en unknown
- 2006-12-01 AT AT06829226T patent/ATE439834T1/de active
- 2006-12-01 DK DK09006788.5T patent/DK2098248T3/da active
- 2006-12-01 DE DE602006008665T patent/DE602006008665D1/de active Active
- 2006-12-01 PT PT09006788T patent/PT2098248E/pt unknown
- 2006-12-01 CN CN2006800455833A patent/CN101321539B/zh not_active Expired - Fee Related
- 2006-12-01 RU RU2008129600/15A patent/RU2465915C2/ru not_active Application Discontinuation
- 2006-12-01 ES ES06829226T patent/ES2330047T3/es active Active
- 2006-12-21 US US11/642,967 patent/US8048910B2/en active Active
-
2008
- 2008-07-09 NO NO20083090A patent/NO20083090L/no not_active Application Discontinuation
-
2009
- 2009-02-10 HK HK09101175.6A patent/HK1123497A1/xx not_active IP Right Cessation
- 2009-09-21 HR HR20090498T patent/HRP20090498T1/hr unknown
- 2009-10-23 CY CY20091101104T patent/CY1110519T1/el unknown
-
2011
- 2011-09-23 US US13/242,241 patent/US8518918B2/en active Active
-
2012
- 2012-08-30 CY CY20121100780T patent/CY1113080T1/el unknown
- 2012-09-06 HR HRP20120708TT patent/HRP20120708T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120708T1 (hr) | Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti | |
JP2007520508A5 (hr) | ||
RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
ECSP024268A (es) | Nuevos polvos para inhalacion que contienen tiotropio | |
DK1326595T3 (da) | Administration af resveratrol til at behandle inflammatoriske respiratoriske lidelser | |
HRP20160285T1 (hr) | Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba | |
HRP20100359T1 (hr) | Specifični glukokortikoidni spoj s protuupalnom aktivnošću | |
IL190835A0 (en) | Sulfonamide derivatives, their preparation and use | |
MX2022012359A (es) | Formulacion. | |
JOP20200314A1 (ar) | تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة | |
CA2733294A1 (en) | Pharmaceutical combination of a tiotropium salt and ciclesonide | |
HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
HRP20050468A2 (en) | Pulverulent formulation for inhalation containing tiotropium | |
RU2019121940A (ru) | Терапевтическая комбинация для лечения развивающейся bpd, содержащая легочный сурфактант и стероид | |
EA201201392A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
WO2021202928A8 (en) | Pharmaceutical compositions of niclosamide | |
UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
US20150038719A1 (en) | Agent for Ameliorating Chronic Obstructive Pulmonary Disease | |
MY191295A (en) | Pharmaceutical composition containing budesonide and formoterol | |
TR2023007360T2 (tr) | A process for the preparation of dry powder compositions for inhalation | |
HRP20170192T1 (hr) | Farmacetuski pripravak za inhalacijsku uporabu koji sadrži kortikoid, te kinolon ili fuzidičnu kiselinu | |
NO20070820L (no) | Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav. |